Current Edition

CMC Biologics Enters into Development and Manufacturing Agreement with Trellis BioScience


Development of Trellis’ monoclonal antibody (mAb) using CMC Biologics’ proprietary CHEF1® Expression Platform and Multi-column Continuous Chromatography (MCC) Technology
Bothell, Washington, Berkeley, California, and Menlo Park, California, USA– July 25, 2017 – CMC ICOS Biologics, Inc., a global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins, and Trellis Bioscience LLC, a private, venture-funded therapeutic antibody company, announced today they have entered into a manufacturing agreement for the process development and production of two of Trellis’ monoclonal antibodies (mAbs).
“Trellis Bioscience is developing human mAb therapies for bacterial and viral infections, and cancer indications, and we have selected CMC Biologics to work with on two of these products. One is for treatment for respiratory syncytial virus (RSV) infections that promises to provide superior post-infection treatment over the currently marketed mAb (palivizumab) by uniquely combining antiviral and anti-inflammatory activity. The other is a first-in-class treatment for bacterial infections that are drug-resistant due to formation of bacterial biofilms; by disrupting the biofilm, TRL1068 acts to resensitize bacteria to conventional antibiotics, with broad-spectrum activity spanning from medically important Gram-positive to Gram-negative bacterial species, inlcluding MRSA and Acinetobacter baumanni. With CMC Biologics’ demonstrated technical expertise, experience, and proprietary CHEF1® Expression System platform, we believe that we have chosen an outstanding CDMO to work with” said Stefan Ryser, PhD, Chief Executive Officer of Trellis Bioscience. “In addition, through their use of Multi-column Continuous Chromatography technology, where a reduced quantity of costly chromatography resins is required in the downstream process, CMC Biologics is able to provide Trellis, a significant reduction in our development and manufacturing costs.”
“We are pleased to be working with Trellis on these two exciting monoclonal antibody products,” said Gustavo Mahler, PhD, Chief Executive Officer of CMC Biologics “With our extensive experience developing monoclonal antibody products, we are delighted to know that we will help deliver Trellis’ antibody treatment for RSV, a leading cause of lower respiratory tract disease in young children as well as their broad-spectrum biofilm disruptor human antibody for reducing the antibiotic resistance that is associated with biofilm formation.